[Activated C protein resistance manifested by cutaneous necrosis after interferon alpha injection: case report].
BACKGROUND
Cutaneous necrosis occurring in the course of treatment by alpha interferon is an uncommon side-effect. Its physiopathologic mechanism remains obscure. A local thrombotic action of interferon has been suggested to explain its occurrence.


METHODS
A 64-year-old male patient with human immunodeficiency virus-related cutaneous Kaposi's sarcoma presented cutaneous necrosis after a 9-month treatment by interferon alpha, while his resistance to activated protein C had already been demonstrated. To our knowledge, this is the first case ever described regarding the association of interferon-induced cutaneous necrosis with activated protein C resistance.


CONCLUSIONS
This suggests that in case of interferon treatment-induced cutaneous necrosis coagulation disorders should be investigated and questions the existence of a particular "pro-coagulant profile" facilitating this side effect.
Plurien
F
F
Service de médecine interne A, centre hospitalier Poissy-Saint-Germain, Saint-Germain-en-Laye, France.
Le Lostec
Z
Z
Pauwels
C
C
Welker
Y
Y
Glaser
C
C
de Mazancourt
P
P
Peltier
J Y
JY
Mornet
P
P
D020016:Activated Protein C Resistance / Q000097:blood / Q000150:complications* / Q000175:diagnosis*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001706:Biopsy; D003875:Drug Eruptions / Q000209:etiology* / Q000473:pathology; D015658:HIV Infections / Q000150:complications; D006801:Humans; D007279:Injections, Subcutaneous; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D009336:Necrosis; D011994:Recombinant Proteins; D012514:Sarcoma, Kaposi / Q000628:therapy / Q000821:virology; D012878:Skin Neoplasms / Q000628:therapy / Q000821:virology; D013997:Time Factors
D000970:Antineoplastic Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins